Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSAs and HSAs to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative.
Monitor tax reform.
Dextromethorphan, Pseudoephedrine restriction issues.
Duration: March 15, 2013
to
December 31, 2017
General Issues: Pharmacy , Taxation/Internal Revenue Code , Health Issues
Spending: about $190,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2017
Mr. Galen Reser terminated an engagement in which they represented Perrigo, Inc. (through FTI Government Affairs) on Jan. 22, 2018.
Original Filing: 300935226.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSAs and HSAs to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on Oct. 20, 2017.
Original Filing: 300913184.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSAs and HSAs to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on July 20, 2017.
Original Filing: 300894654.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSAs and HSAs to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on April 13, 2017.
Original Filing: 300865410.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSAs and HSAs to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on Jan. 12, 2017.
Original Filing: 300845483.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on Oct. 17, 2016.
Original Filing: 300829319.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on July 19, 2016.
Original Filing: 300815098.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on April 20, 2016.
Original Filing: 300801005.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on Jan. 20, 2016.
Original Filing: 300782541.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on Oct. 19, 2015.
Original Filing: 300758192.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on July 13, 2015.
Original Filing: 300733675.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on April 15, 2015.
Original Filing: 300716452.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. Monitored Fairness to Pet Owners Act.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on Jan. 20, 2015.
Original Filing: 300704309.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, H.R. 2835, "Restoring Access to Medication Act of 2013." FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor tax reform. Monitor developments related to the Camp Tax Proposal.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
In Q3, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on Oct. 14, 2014.
Original Filing: 300676382.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, H.R. 2835, "Restoring Access to Medication Act of 2013." FDA's proposed changes to generic drug labeling. FDA's proposed Infant Formula regulations. House Energy and Commerce 21st Century Cures Initiative.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitor tax reform. Monitor developments to the Camp Tax Proposal.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan. Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on July 15, 2014.
Original Filing: 300657258.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, H.R. 2835, "Restoring Access to Medication Act of 2013." FDA's proposed changes to generic drug labeling. FDA's proposed Infant Formula regulations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor tax reform. Monitor developments related to the Camp Tax Proposal.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on April 16, 2014.
Original Filing: 300637886.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, H.R. 2835, "Restoring Access to Medication Act of 2013." FDA's proposed changes to generic drug labeling.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor tax reform. Monitor developments related to the Camp Tax Proposal.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2013
In Q4, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on Jan. 16, 2014.
Original Filing: 300615947.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, H.R. 2835, "Restoring Access to Medication Act of 2013." Encourage the FTC to promulgate rules relating to veterinary prescriptions, including rules requiring the prescribers of an animal drug to: 1. Provide the pet owners a copy of the veterinary prescription and a written disclosure that the pet owner may fill the prescription through the prescriber (if available) or through another pharmacy determined by the pet owner. H.R. 1919, "Safeguarding America's Pharmaceuticals Act of 2013." S. 959, "Pharmaceutical Quality, Security and Accountability Act." Passed the Congress. Signed into law on 11/27/2013. H.R. 3204, "Drug Quality and Security Act." FDA proposed rule on labeling changes for ANDA holders titled Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, Docket No. FDA-2013-N-0500.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2013
Mr. Galen Reser amended a lobbying report for representation of Perrigo, Inc. (through FTI Government Affairs) in Q42013 on Jan. 16, 2014.
Original Filing: 300616730.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, H.R. 2835, "Restoring Access to Medication Act of 2013." Encourage the FTC to promulgate rules relating to veterinary prescriptions, including rules requiring the prescribers of an animal drug to: 1. Provide the pet owners a copy of the veterinary prescription and a written disclosure that the pet owner may fill the prescription through the prescriber (if available) or through another pharmacy determined by the pet owner. H.R. 1919, "Safeguarding America's Pharmaceuticals Act of 2013." S. 959, "Pharmaceutical Quality, Security and Accountability Act." Passed the Congress. Signed into law on 11/27/2013. H.R. 3204, "Drug Quality and Security Act." FDA proposed rule on labeling changes for ANDA holders titled Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, Docket No. FDA-2013-N-0500.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2013
In Q3, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on Oct. 21, 2013.
Original Filing: 300605948.xml
Lobbying Issues
Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, H.R. 2835, "Restoring Access to Medication Act of 2013." Encourage the FTC to promulgate rules relating to veterinary prescriptions, including rules requiring the prescribers of an animal drug to: 1. Provide the pet owners a copy of the veterinary prescription and a written disclosure that the pet owner may fill the prescription through the prescriber (if available) or through another pharmacy determined by the pet owner. H.R. 1919, "Safeguarding America's Pharmaceuticals Act of 2013." S. 959, "Pharmaceutical Quality, Security and Accountability Act." H.R. 3204, "Drug Quality and Security Act."
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2013
In Q2, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) , earning $10,000. The report was filed on July 19, 2013.
Original Filing: 300578001.xml
Lobbying Issues
OTC medication eligibility under Flexible Spending Accounts, S.312/H.R.605, The Patients' Freedom to Choose Act; Drug Regulation; FDA reform; PDUFA, H.R.3630. Pharmaceutical traceability. Rx OTC switch. Rx TEC. GDUFA H.R.5651, S.3187. Fairness to Pet Owners Act.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2013
In Q1, Mr. Galen Reser lobbied for Perrigo, Inc. (through FTI Government Affairs) . The report was filed on April 23, 2013.
Original Filing: 300565060.xml
Lobbying Issues
OTC medication eligibility under Flexible Spending Accounts, S.312/H.R.605, The Patients' Freedom to Choose Act; Drug Regulation; FDA reform; PDUFA, H.R.3630. Pharmaceutical traceability. Rx OTC switch. Rx TEC. GDUFA H.R.5651, S.3187. Fairness to Pet Owners Act.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Dextromethorphan, Pseudoephedrine restriction issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2013
Mr. Galen Reser filed a lobbying registration on April 22, 2013 to represent Perrigo (through FTI Government Affairs), effective March 15, 2013.
Original Filing: 300564190.xml
Issue(s) they said they’d lobby about: OTC medication eligibility under Flexible Spending Accounts, S.312/H.R.605, The Patients' Freedom to Choose Act; Drug Regulation; FDA reform; PDUFA, H.R.3630. Pharmaceutical traceability. Rx OTC switch. Rx TEC. GDUFA H.R.5651, S.3187. Fairness to Pet Owners Act. Monitor tax reform. Dextromethorphan, Pseudoephedrine restriction issues. .
1st Quarter, 2013
Mr. Galen Reser filed a lobbying registration on April 18, 2013 to represent Perrigo, effective March 15, 2013.
Original Filing: 300553971.xml
Issue(s) they said they’d lobby about: OTC medication eligibility under Flexible Spending Accounts, S.312/H.R.605, The Patients' Freedom to Choose Act; Drug Regulation; FDA reform; PDUFA, H.R.3630. Pharmaceutical traceability. Rx OTC switch. Rx TEC. GDUFA H.R.5651, S.3187. Fairness to Pet Owners Act. Monitor tax reform. Dextromethorphan, Pseudoephedrine restriction issues. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...